Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model

BMC Microbiology

Research

Seyed Mahmoud Amin Marashi¹  Farhad Nikkhahi¹  Amir Javadi²  Farshad Foroughi³  Sara Rahimi⁴  Mehdi Bakht⁴ 

[1] Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran;Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran;Department of Community Medicine, Qazvin University of Medical Sciences, Qazvin, Iran;Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran;Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran;Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran;Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran;

关键词: Bacteriophage;    Hypervirulent;    Klebsiella pneumoniae;    β-lactamase;    Biofilm;    Mice model;   

DOI  :  10.1186/s12866-023-02979-7

 received in 2023-04-22, accepted in 2023-08-14,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundSevere infections caused by β- lactamase producers, hypervirulent Klebsiella pneumoniae (BhvKp) with K2 serotype, highlight emergency need for new therapeutic strategies against this pathogen. We aimed to assess the efficacy of a novel phage, PSKP16, in the treating of pneumonia induced by BhvKp in mice models.MethodGenome sequences of PSKP16 were analyzed, and associated information can be found in NCBI. We applied treatment in two ways: by using mice for immediate and delayed treatments. Moreover, acute pneumonia obtained by BhvKp with intranasal method, was characterized in terms of histopathology of pulmonary lesions, biomarkers of inflammation level, leukocytes cells infiltration extent in mice, and was assessed treatment of them with PSKP16 multiplicity of infection (MOI: 10), either individually or in combination with gentamicin. Assessment of the ability of PSKP16 to inhibit BhvKp biofilm was studied.ResultsPSKP16 was associated with the Drexlerviridae family, and had a genome size of 46,712 bp, and 67 predicted ORFs. Herein, prompt phage administration’s efficacy to decrease bacterial load and improve the survival rate in pneumonia models was faster than the synergism model with delay, but both almost displayed similar endpoints. The distribution of BhvKp strains in the lung was consistent with the histopathological findings, simultaneous inflammation, and level of serum tumor necrosis factor-α (TNF α). The phage treatment presented a lack of severe lesions and alveolar edema, reduction of inflammatory cell infiltration, which not only was it not associated with an over-inflammation but also provided a faster correction of blood cell count abnormalities compared to gentamicin. Phage with a high concentration in in vitro model effectively eliminated biofilms.ConclusionIt is essential to raise clinical awareness and management of BhvKp infections, signaled as the next superbug in waiting. The results of our study underscore the importance of PSKP16 as a phage with promising therapeutic potential in treating BhvKp-induced pneumonia.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

40517_2023_266_Article_IEq67.gif

40517_2023_266_Article_IEq62.gif

40517_2023_266_Article_IEq42.gif

40517_2023_266_Article_IEq38.gif

Fig. 5